Details for Patent: 11,529,362

Which drugs does patent 11,529,362 protect, and when does it expire?

Patent 11,529,362 protects AKYNZEO and is included in one NDA.

This patent has forty-six patent family members in thirty-seven countries.

Summary for Patent: 11,529,362

Title:	Physiologically balanced injectable formulations of fosnetupitant
Abstract:	Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
Inventor(s):	Alessio Venturini, Roberta Cannella
Assignee:	Helsinn Healthcare SA
Application Number:	US16/817,683
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 11,529,362

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	POWDER;INTRAVENOUS	210493-001	Apr 19, 2018		DISCN	Yes	No	11,529,362		Y
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	SOLUTION;INTRAVENOUS	210493-002	May 27, 2020		RX	Yes	Yes	11,529,362		Y

International Family Members for US Patent 11,529,362

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	108676
Australia	2017276588
Brazil	112018074655